Resolve the complexity of your ADCs
Monoclonal antibodies (mAbs) are a growing class of therapeutic proteins that can be used to target proteins with great selectivity. With this high selective power, specific cells mechanisms can be modified such as tumor growth inhibition in oncology indications.
The added complexity of combining a cleavable linker and a cytotoxic drug to an already complex monoclonal antibody product requires improved analytical methods. It is not only necessary to control the antibody drug conjugate expected protein micro-heterogeneities but also the drug loading, the drug-to-antibody ratio (DAR), the amount of free antibody and drug, and the linker chemistry.
The dynamic range of Bruker ultrahigh resolution QTOF such as maXis II is a key element for the successful characterization of ADCs.
A key ADC assay is the determination of the drug distribution profile. This often needs to be performed in native conditions and in the presence of heterogeneity such as glycosylation and formulation impurities. The ability to measure the ADC signal with accurate relative intensities in the presence of these interferences makes the maXis II with high mass option the preferred instrument for drug distribution measurements.